| scholarly article | Q13442814 |
| P50 | author | Tada Kunavisarut | Q87694832 |
| Nattakarn Suwansaksri | Q88926066 | ||
| Lukana Preechasuk | Q88926068 | ||
| P2093 | author name string | Tada Kunavisarut | |
| Lukana Preechasuk | |||
| Nattakarn Suwansaksri | |||
| P2860 | cites work | Role of Cholestyramine in Refractory Hyperthyroidism: A Case Report and Literature Review | Q26799840 |
| Graves' Disease Mechanisms: The Role of Stimulating, Blocking, and Cleavage Region TSH Receptor Antibodies | Q27687742 | ||
| Thyrotropin Receptor Epitope and Human Leukocyte Antigen in Graves' Disease | Q28068607 | ||
| The use of lithium in the treatment of thyrotoxicosis | Q28362755 | ||
| Graves' Disease. | Q30243909 | ||
| Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring | Q33431424 | ||
| Lithium intoxication | Q33540440 | ||
| Targeted biological therapies for Graves' disease and thyroid-associated ophthalmopathy. Focus on B-cell depletion with Rituximab | Q33741009 | ||
| Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein | Q33869893 | ||
| Small molecule TSHR agonists and antagonists | Q33879256 | ||
| Iodine-Induced hypothyroidism | Q33950448 | ||
| Lithium use in special populations | Q33985019 | ||
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor | Q33993842 | ||
| The effect of combination therapy with propylthiouracil and cholestyramine in the treatment of Graves' hyperthyroidism | Q46457255 | ||
| Rituximab in relapsing Graves' disease, a phase II study. | Q46483075 | ||
| Assessment and management of bipolar disorder: summary of updated NICE guidance. | Q50620704 | ||
| Therapeutic effectiveness of potassium iodine in drug-naïve patients with Graves' disease: a single-center experience. | Q50726110 | ||
| The feasibility of low-dose oral lithium therapy and its effect on thyroidal radioiodine uptake, retention, and hormonal parameters in various subcategories of hyperthyroid patients: a pilot study. | Q53663857 | ||
| Serum Thyroxine and Triiodothyronine Concentrations During Iodide Treatment of Hyperthyroidism | Q53717150 | ||
| The effect of iodide on serum thyroid hormone levels in normal persons, in hyperthyroid patients, and in hypothyroid patients on thyroxine replacement | Q53799357 | ||
| The inhibitory effect of lithium on thyroid hormone release in both euthyroid and thyrotoxic patients. | Q53831221 | ||
| 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. | Q54429935 | ||
| Lithium acetate, a useful and well tolerated thyrostatic for selected cases of hyperthyroidism | Q67027432 | ||
| Levothyroxine-cholestyramine interaction reemphasized | Q67973612 | ||
| Thyroid secretion in vitro: inhibition of TSH and dibutyryl cyclic-AMP stimulated 131-I release by Li+1 | Q68624604 | ||
| Inhibitory effect of lithium on the release of thyroid hormones from thyrotropin-stimulated mouse thyroids in a perifusion system | Q69054095 | ||
| Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism | Q71245020 | ||
| Treatment of hyperthyroidism with a combination of methimazole and cholestyramine | Q71477142 | ||
| The Influence of Cholestyramine on Thyroxine Absorption | Q72525327 | ||
| Effect of perchlorate on the human thyroid gland | Q72994740 | ||
| Lithium treatment in amiodarone-induced thyrotoxicosis | Q73498870 | ||
| Duodenal obstruction in thyroid storm | Q73914573 | ||
| B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study | Q79734838 | ||
| Plasma adrenocorticotropin (ACTH) values and cortisol response to 250 and 1 microg ACTH stimulation in patients with hyperthyroidism before and after carbimazole therapy: case-control comparative study | Q79843050 | ||
| Use of lithium in the treatment of thyrotoxicosis | Q80122760 | ||
| Amiodarone and the thyroid | Q81912240 | ||
| [Use of lithium carbonate for the treatment of amiodarone-induced thyrotoxicosis] | Q82861471 | ||
| Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism | Q85229504 | ||
| Remission after potassium iodide therapy in patients with Graves' hyperthyroidism exhibiting thionamide-associated side effects | Q87632656 | ||
| Opposite Effects of Dexamethasone on Serum Concentrations of 3, 3′,5′-Triiodothyronine (Reverse T3) and 3,3′,5′-Triiodothyronine (T3) | Q34158309 | ||
| Perchlorate clinical pharmacology and human health: a review | Q34321846 | ||
| Perchlorate and the thyroid gland | Q34464781 | ||
| A new small-molecule antagonist inhibits Graves' disease antibody activation of the TSH receptor | Q34622464 | ||
| Plasma inorganic iodide as a homeostatic regulator of thyroid function. | Q34853834 | ||
| In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70). | Q35309042 | ||
| Blocking type TSH receptor antibodies | Q35309934 | ||
| Inhibition by iodine of the release of thyroxine from the thyroid glands of patients with thyrotoxicosis | Q35574029 | ||
| Targeting the thyroid-stimulating hormone receptor with small molecule ligands and antibodies | Q35794921 | ||
| Antithyroid drugs | Q36061115 | ||
| Mechanism of action of a nanomolar potent, allosteric antagonist of the thyroid-stimulating hormone receptor | Q36147341 | ||
| Update in TSH receptor agonists and antagonists | Q36442422 | ||
| The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option. | Q36462675 | ||
| Thyrotoxicosis and thyroid storm | Q36663921 | ||
| A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism | Q37034874 | ||
| A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice | Q37405158 | ||
| Iodine excess | Q37695909 | ||
| Approach to the patient with amiodarone-induced thyrotoxicosis | Q37762924 | ||
| Management of severe thyrotoxicosis when the gastrointestinal tract is compromised | Q37831340 | ||
| Lithium as an adjunct to radioactive iodine for the treatment of hyperthyroidism: a systematic review and meta-analysis | Q38209154 | ||
| 2016 Guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society (First edition). | Q38811030 | ||
| Lithium carbonate in the treatment of thyrotoxicosis. A controlled trial | Q39369163 | ||
| Lithium as an adjunct to radioiodine therapy for thyrotoxicosis | Q39369195 | ||
| Pre-Operative Lugol's Iodine Treatment in the Management of Patients Undergoing Thyroidectomy for Graves' Disease: A Review of the Literature | Q39371058 | ||
| Thyroid hormone and the gut. | Q39526012 | ||
| A human monoclonal autoantibody to the thyrotropin receptor with thyroid-stimulating blocking activity | Q39960903 | ||
| Iodolactones and iodoaldehydes--mediators of iodine in thyroid autoregulation | Q41289452 | ||
| Studies on the mechanism of acute inhibition of thyroglobulin hydrolysis by iodine. | Q41917266 | ||
| Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample | Q43021378 | ||
| Benefit of short-term iodide supplementation to antithyroid drug treatment of thyrotoxicosis due to Graves' disease | Q43242672 | ||
| Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. | Q43244160 | ||
| Adrenocortical reserves in patients with Graves' disease | Q43525323 | ||
| Treatment of thyrotoxicosis with lithium carbonate | Q43605544 | ||
| Acute Effects of Corticosteroids on Thyroid Activity in Graves' Disease | Q43869164 | ||
| Treatment with lithium prevents serum thyroid hormone increase after thionamide withdrawal and radioiodine therapy in patients with Graves' disease | Q44168050 | ||
| Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. | Q44661760 | ||
| Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease | Q45282049 | ||
| Potential utility of rituximab for Graves' orbitopathy | Q45719549 | ||
| Low doses of cholestyramine in the treatment of hyperthyroidism | Q46301124 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 5794054 | |
| P577 | publication date | 2018-04-22 | |
| P1433 | published in | International journal of endocrinology | Q26842119 |
| P1476 | title | Nonthionamide Drugs for the Treatment of Hyperthyroidism: From Present to Future | |
| P478 | volume | 2018 |
| Q92240412 | Thyrotoxic Periodic Paralysis: A Spine Consultation | cites work | P2860 |
Search more.